|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||10.75 - 11.50|
|52 Week Range||4.48 - 14.71|
|Beta (5Y Monthly)||1.94|
|PE Ratio (TTM)||10.80|
|Earnings Date||Aug 05, 2019 - Aug 09, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shares of GW Pharmaceuticals (NASDAQ: GWPH) are up by 4.8% as of 3:18 p.m. EDT on Monday, after rising by as much as 5.5% earlier in the day. The catalyst for these nice gains is the fact that the U.S. Food and Drug Administration (FDA) approved GW Pharma's Epidiolex for the treatment of seizures associated with tuberous sclerosis complex (TSC). Back in June of 2018, Epidiolex was approved for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, thus becoming the first cannabis-derived drug to be approved by the FDA.
The company's star CBD drug can now be prescribed for a new condition, and its age range for a previous approval has been expanded.
Shares of GW Pharmaceuticals rallied 5.0% in trading on Monday after the drugmaker said its cannabinoid drug Epidiolex had received approval from the Food and Drug Administration for a new indication. The drug, which is the first cannabinoid-based treatment to receive FDA approval, is now approved to treat seizures associated with tuberous sclerosis complex, a rare disease that affects about 50,000 people in the U.S. SVB Leerink's Marc Goodman wrote in an investor note that the new indication will add "a sizeable bump that we think could boost the sales trajectory of Epidiolex over the next few years." GW's stock has gained 28.3% year-to-date, while the S&P 500 is up 1.2%.